Chemotherapy Supported by Autologous Hematopoietic Stem Cells
ConditionOvarian Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-60
SponsorChongqing University Cancer Hospital
About this trial
The aim of this project is to use autologous haematopoietic stem cell transfusion support to promote the reconstruction of haematopoietic function after chemotherapy for ovarian cancer. To explore the impact of stored haematopoietic stem cell support therapy on bone marrow protection after conventional chemotherapy for ovarian cancer in order to facilitate its clinical application.
Eligibility criteria
Qualifiers
18-60 years old;
there are chemotherapy indicators for ovarian cancer;
ovarian cancer diagnosed by histopathology;
recurrent and metastatic ovarian cancer;
Disqualifiers
patients with bone marrow disease;
central nervous system or soft meningeal or bone or bone marrow metastases confirmed by imaging or pathology;
patient has severe cardiac insufficiency;
previous history of allogeneic stem cell transplantation or organ transplantation;
Trial design
Treatments tested in this trial
- Autologous blood transfusion with haematopoietic stem cells
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov